LOTTE BIOLOGICS Accelerates Global CDMO Expansion with Dual Manufacturing Bases in North America and Asia, and Next-Generation ADC Modalities

This year, LOTTE BIOLOGICS has ramped up its CDMO business expansion with the completion of an ADC (Antibody-Drug Conjugate) facility expansion at its Syracuse Bio Campus in the U.S. and the signing of its first production contract.